How to Fight HIV PrEP and Treatment Denials: A Step-by-Step Guide for Patients

HIV pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) are among the most effective preventive and therapeutic interventions in modern medicine—yet they're also among the most frequently denied or restricted by insurers. If you're HIV-negative and seeking PrEP (Truvada, Descovy, or Apretude), federal law under the Affordable Care Act requires your insurer to cover it with zero cost-sharing—no copay, no coinsurance, no deductible—because the U.S. Preventive Services Task Force gave PrEP a Grade A recommendation in 2019. If you're living with HIV and your doctor prescribes a single-tablet regimen like Biktarvy, Dovato, or long-acting injectable Cabenuva, insurers still deploy step therapy, prior authorization, and formulary exclusions that contradict the Department of Health and Human Services (DHHS) guidelines used by every HIV specialist in the country. This guide walks you through the most common denial tactics, the specific clinical evidence and policy citations that overturn them, and the concrete steps to build a winning appeal.

---

Why Insurers Deny HIV PrEP and Treatment

1. Charging copays, coinsurance, or deductibles for PrEP

The most pervasive violation: insurers impose $20–$100+ copays on Descovy or generic Truvada for PrEP, or apply PrEP to your deductible, even though the ACA explicitly prohibits cost-sharing for USPSTF Grade A preventive services. Some plans claim the "$0 PrEP" rule applies only to generic Truvada (TDF/FTC), not branded Descovy (TAF/FTC) or Apretude (long-acting injectable cabotegravir).

2. Denying Apretude (cabotegravir long-acting injectable) as "non-formulary" or "not medically necessary"

Insurers relegate Apretude to non-preferred tiers or deny it outright, demanding patients "fail" oral PrEP first. This ignores the HPTN 083 and HPTN 084 trials (published in NEJM 2021), which demonstrated superior efficacy to oral TDF/FTC, and the July 2021 HHS FAQ Part 47 clarification that plans must cover at least one medication in each PrEP modality (oral daily TDF/FTC, oral daily TAF/FTC, and long-acting injectable cabotegravir) without cost-sharing.

3. Step therapy: forcing "trial and failure" of older or contraindicated regimens

For HIV treatment, insurers require patients to fail Dovato (dolutegravir/lamivudine) before approving Biktarvy (bictegravir/emtricitabine/TAF) or Triumeq—even when the patient has hepatitis B co-infection (which makes Dovato inappropriate, since it lacks activity against HBV), renal impairment (where TAF is preferred over TDF), or a viral load >500,000 copies/mL (a documented exclusion criterion for Dovato per DHHS guidelines). Similarly, insurers demand "failure" of oral ART before covering Cabenuva (cabotegravir/rilpivirine long-acting injectable), ignoring the ATLAS and ATLAS-2M trials showing non-inferiority and the DHHS guidelines listing Cabenuva as a recommended option for virologically suppressed patients seeking injection-based therapy.

4. "Not FDA-approved" or "off-label" denials for event-driven (on-demand) PrEP or infant prophylaxis

Some plans deny event-driven PrEP dosing (2-1-1 regimen: 2 pills 2–24 hours before sex, 1 pill 24 hours after, 1 pill 48 hours after) citing lack of FDA approval, even though the DHHS/CDC PrEP guideline (2021 update) endorses it for cisgender men who have sex with men. Infant HIV prophylaxis regimens may be denied as "experimental."

5. Formulary exclusions and "therapeutic substitution" mandates

Insurers exclude single-tablet regimens (Biktarvy, Genvoya, Symtuza, Odefsey) from formulary, or require "therapeutic substitution" to multi-pill generic combinations—ignoring adherence data showing that single-tablet regimens improve viral suppression rates and that pill burden is a documented barrier to adherence, especially for patients with mental health conditions, substance use disorders, or homelessness.

---

The Citations Insurers Respect

When you appeal, reference specific guidelines, trials, and federal mandates by name and year. Vague statements like "my doctor says I need this" won't work. Here are the key authorities:

Federal Mandates & Policy

• USPSTF 2019 Grade A Recommendation for PrEP in persons at increased risk of HIV acquisition (reaffirmed 2023)
• ACA § 2713 (42 U.S.C. § 300gg-13): Non-grandfathered health plans must cover USPSTF Grade A/B preventive services with zero cost-sharing when delivered by in-network providers
• HHS/CMS/DOL/Treasury FAQ Part 47 (July 19, 2021): Clarifies that PrEP coverage without cost-sharing includes the medication and ancillary services (HIV/STI/HCV/HBV testing, creatinine/renal panels, pregnancy testing, PrEP-related office visits, adherence counseling). Plans must cover at least one option in each PrEP modality: oral TDF/FTC, oral TAF/FTC, and long-acting injectable cabotegravir.

Clinical Guidelines

• DHHS Adult and Adolescent ARV Guidelines (2024 update): The gold standard for HIV treatment in the U.S., updated continuously at clinicalinfo.hiv.gov. Lists Biktarvy, dolutegravir-based regimens (including Dovato and Triumeq), and Cabenuva as recommended initial or switch regimens depending on clinical context.
• DHHS/CDC PrEP Clinical Practice Guideline (2021 update): Recommends PrEP for all persons at substantial risk; endorses oral TDF/FTC, oral TAF/FTC, and injectable cabotegravir; supports event-driven dosing (2-1-1) for MSM.
• DHHS Perinatal Guidelines: Now lists dolutegravir as preferred in pregnancy (based on updated Tsepamo safety data).
• DHHS Pediatric ARV Guidelines: Guides treatment for HIV-exposed infants and children.

Pivotal Trials (cite by name and journal)

• HPTN 083 (NEJM 2021): Long-acting injectable cabotegravir (Apretude) superior to oral TDF/FTC for PrEP in cisgender men and transgender women who have sex with men.
• HPTN 084 (NEJM 2021): Cabotegravir LA superior to oral TDF/FTC for PrEP in cisgender women.
• DISCOVER trial (Lancet 2020): TAF/FTC (Descovy) non-inferior to TDF/FTC (Truvada) for PrEP, with improved bone and renal safety markers.
• ATLAS / ATLAS-2M (Lancet 2020, AIDS 2021): Cabotegravir/rilpivirine LA (Cabenuva) non-inferior to daily oral ART; ATLAS-2M showed every-2-month dosing non-inferior to monthly.
• GEMINI-1 and GEMINI-2 (Lancet 2019): Dolutegravir/lamivudine (Dovato) non-inferior to dolutegravir + TDF/FTC in ARV-naive patients with baseline viral load ≤500,000 copies/mL and no HBV co-infection.
• GS-US-380-1489, GS-US-380-1490 (Biktarvy registration trials, Lancet HIV 2018): Bictegravir/TAF/FTC non-inferior to dolutegravir + TAF/FTC and to abacavir/dolutegravir/lamivudine in treatment-naive adults.

---

How to Argue Against Each Major Denial Reason

Denial: "You owe a copay/deductible for PrEP"

Concrete steps:

1. Verify your plan type. ACA § 2713 applies to non-grandfathered plans. If your plan started after March 23, 2010, or has made significant changes since, it's almost certainly non-grandfathered. Call your insurer and ask, "Is this plan grandfathered under the ACA?" Document the answer.

2. Confirm the prescription is written for PrEP (not treatment). The $0 cost-sharing rule applies only to preventive services. Your prescription and diagnosis codes must indicate HIV prevention (ICD-10 Z20.6, "Contact with and exposure to HIV," or Z79.899 for "long-term prophylactic drug use"). If you're HIV-positive, ACA § 2713 does not apply; you'll argue medical necessity instead.

3. Cite the law in your appeal. Example language:

> "Under ACA § 2713 and the USPSTF 2019 Grade A recommendation (reaffirmed 2023), my plan is required to cover PrEP medications without cost-sharing. HHS FAQ Part 47 (July 19, 2021) explicitly states that this includes 'at least one drug in each available PrEP modality'—oral TDF/FTC, oral TAF/FTC, and long-acting injectable cabotegravir. [Plan name] has charged me a $[amount] copay for [Descovy / Apretude], which violates federal law. I request an immediate refund of all cost-sharing collected and prospective coverage at $0."

4. If they argue "only generic Truvada is $0," respond:

> "HHS FAQ Part 47 requires coverage of at least one option in each modality. Descovy (TAF/FTC) is the only FDA-approved oral TAF-based PrEP; it is not interchangeable with TDF/FTC for patients with renal impairment [if applicable, cite eGFR], osteoporosis [cite DXA T-score], or those at risk for bone/kidney toxicity. The FAQ does not permit plans to limit $0 coverage to a single drug when clinically distinct options exist within a modality."

5. File a complaint. If the insurer refuses, file with your state insurance commissioner and the U.S. Department of Labor (for employer plans) or CMS (for marketplace plans). Include your appeal, the denial, and receipts.

---

Denial: "Apretude (cabotegravir LA injectable) is not medically necessary; use oral PrEP"

Concrete steps:

1. Document substantial HIV risk. PrEP is indicated for anyone at substantial risk. CDC/DHHS criteria include: condomless sex with a partner of unknown status, STI in the past 6 months, sex work, injection drug use, or a partner living with HIV not virally suppressed. Gather records: recent STI diagnoses, PrEP-related lab orders, clinical notes documenting sexual history.

2. Document oral PrEP adherence challenges or contraindications. Example justifications for Apretude:

- Adherence barriers: "I missed ≥3 doses of Truvada over the past 6 months due to [pill fatigue / depression / stigma / homelessness]. Long-acting injectable PrEP eliminates daily adherence burden." (Attach pharmacy refill records showing gaps.)

- Renal or bone concerns: "I have CKD stage 3a (eGFR 52 mL/min) and cannot tolerate TDF. I experienced nausea and headache on Descovy (TAF/FTC) and discontinued after 3 weeks." (Attach lab results, clinical notes.)

- Privacy/stigma: "Daily pill bottles risk disclosure of my HIV prevention status in my household, which is not safe. Bi-monthly injections at the clinic protect my privacy and safety."

3. Cite the evidence. Example language:

> "Apretude (cabotegravir LA) is FDA-approved for PrEP (December 2021) and endorsed by the DHHS/CDC PrEP Clinical Practice Guideline (2021 update). The HPTN 083 trial (NEJM 2021) demonstrated a 66% relative risk reduction compared to oral TDF/FTC in cisgender MSM and transgender women; HPTN 084 (NEJM 2021) showed 90% reduction in cisgender women. HHS FAQ Part 47 (July 2021) requires coverage of 'at least one option in each PrEP modality,' explicitly including long-acting injectable cabotegravir. My plan's denial contradicts federal guidance."

4. Pre-empt "step therapy" arguments:

> "The FAQ does not permit step therapy for PrEP modalities. Requiring 'failure' of oral PrEP is clinically inappropriate when I have documented adherence barriers [or contraindications]. Step therapy increases my risk of HIV acquisition during the mandated 'trial' period—a preventable harm."

---

Denial: "Biktarvy is not medically necessary; use Dovato or generic combination"

Concrete steps:

1. Check for Dovato contraindications. Per DHHS guidelines, Dovato (dolutegravir/lamivudine) is not recommended if:

- Hepatitis B co-infection (HBsAg-positive): Dovato lacks tenofovir or emtricitabine, which treat HBV. Discontinuing these agents risks HBV flare.

- Baseline viral load >500,000 copies/mL (for treatment-naive patients): GEMINI trials excluded this group.

- HIV genotype unavailable before treatment start (for treatment-naive patients).

- Resistance to dolutegravir or lamivudine.

2. Gather labs and resistance history. Obtain HBsAg, HCV antibody, baseline or nadir CD4, HIV RNA, genotype/resistance report, and eGFR from your provider. If HBsAg-positive, this alone disqualifies Dovato.

3. Cite the guidelines. Example:

> "I am HBsAg-positive (hepatitis B surface antigen confirmed [date], result attached). Per DHHS Adult ARV Guidelines (2024), dolutegravir/lamivudine (Dovato) is contraindicated in persons with HBV co-infection because it does not suppress HBV replication. Biktarvy (bictegravir/emtricitabine/TAF) is a DHHS-recommended initial regimen that treats both HIV and HBV. Forcing me onto Dovato would leave my hepatitis B untreated and risk hepatic flare, cirrhosis, and liver failure."

4. If the issue is renal function:

> "My eGFR is [value] mL/min. Biktarvy contains TAF (tenofovir alafenamide), which has superior renal and bone safety compared to TDF (tenofovir disoproxil fumarate) per the DISCOVER trial (Lancet 2020) and is preferred in patients with CKD per DHHS guidelines. Generic TDF-based regimens are contraindicated or suboptimal given my kidney function."

5. If the issue is adherence/pill burden:

> "Biktarvy is a single-tablet, once-daily regimen. Generic 'combination' regimens require multiple pills daily, which decreases adherence—a documented risk factor for virologic failure (e.g., JAIDS 2018; doi:10.1097/QAI.0000000000001634). DHHS guidelines list single-tablet regimens as recommended options specifically to optimize adherence."

---

Denial: "Cabenuva (long-acting injectable ART) is not medically necessary; use oral ART"

Concrete steps:

1. Confirm eligibility per DHHS guidelines. Cabenuva is recommended for adults who:

- Are virologically suppressed (HIV RNA <50 copies/mL) on a stable regimen for ≥6 months.

- Have no history of treatment failure or resistance to cabotegravir or rilpivirine.

- Have no hepatitis B co-infection (Cabenuva does not treat HBV).

2. Document the reason for switching. Example justifications:

- Adherence challenges: "I have bipolar disorder and frequently miss doses during depressive episodes. Over the past year, I've had 4 episodes of detectable viremia (most recent: 180 copies/mL on [date]) due to missed pills. Bi-monthly injections eliminate daily adherence burden." (Attach psychiatric records, viral load trend.)

- Pill fatigue / treatment burnout: "I have been on daily oral ART for 12 years. I am virologically suppressed but experiencing pill fatigue and requesting a switch to long-acting therapy to sustain long-term adherence."

- Privacy/stigma: "I live in a setting where daily pill bottles risk unwanted disclosure of my HIV status."

3. Cite the evidence. Example:

> "Cabenuva (cabotegravir/rilpivirine long-acting injectable) is FDA-approved (January 2021) and listed as a recommended regimen for virologically suppressed adults in the DHHS Adult ARV Guidelines (2024 update). The ATLAS trial (Lancet 2020) and ATLAS-2M (AIDS 2021) demonstrated non-inferiority to continued oral ART, with high patient satisfaction and superior adherence. I meet all eligibility criteria: undetectable viral load for [duration], no resistance to cabotegravir or rilpivirine, no HBV co-infection (HBsAg negative [date])."

4. Address cost objections:

> "While Cabenuva's acquisition cost is higher than generics, the clinical and public health value of sustained viral suppression—via improved adherence—reduces downstream costs (hospitalizations, resistance, transmission). Cost alone is not a valid basis for denying a guideline-recommended regimen when the patient meets clinical criteria."

---

Denial: "Descovy PrEP is not covered; use generic Truvada"

Concrete steps:

1. Identify contraindications or tolerability issues with TDF. Descovy (TAF/FTC) is preferred over Truvada (TDF/FTC) for patients with:

- Renal impairment: eGFR 30–59 mL/min (TAF has lower tenofovir plasma exposure).

- Osteoporosis or fracture history: TAF causes smaller decreases in bone mineral density than TDF (DISCOVER trial).

- GI intolerance to TDF.

2. Cite the evidence and HHS FAQ Part 47:

> "HHS FAQ Part 47 requires coverage of 'at least one drug in each PrEP modality,' including oral TAF/FTC. The DISCOVER trial (Lancet 2020) showed Descovy non-inferior to Truvada for PrEP efficacy, with significantly smaller declines in bone mineral density and improved renal biomarkers. I have [osteopenia (DXA T-score -2.1) / CKD stage 3a (eGFR 48 mL/min)], making TAF-based PrEP medically preferred. My plan's refusal to cover Descovy violates the FAQ's requirement and exposes me to preventable bone or kidney injury."

3. If cost-sharing was applied, demand $0 coverage per ACA § 2713 (see first denial argument above).

---

What We Do

We generate physician-ready appeal letters in under 10 minutes. You answer questions about your diagnosis, treatment history, labs, and the denial reason; our engine drafts a letter citing the specific DHHS guidelines, pivotal trials (HPTN 083, ATLAS-2M, GEMINI, DISCOVER), USPSTF recommendations, ACA mandates, and HHS FAQs that apply to your case. The letter is written for your doctor to review, sign, and submit on your behalf. We don't practice medicine, and we don't provide legal advice—we translate the clinical evidence and federal law into the language insurers respond to. If your first appeal is denied, we help you escalate to external review and, when appropriate, file complaints with state and federal regulators. Most appeals succeed at the first or second level when the evidence is cited correctly.

---

Sources

1. U.S. Preventive Services Task Force. Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;321(22):2203–2213. doi:10.1001/jama.2019.6390 (Grade A; reaffirmed 2023)

2. Affordable Care Act § 2713 (42 U.S.C. § 300gg-13): Coverage of preventive health services.

3. U.S. Departments of Health and Human Services, Labor, and Treasury. FAQs About Affordable Care Act Implementation Part 47 (July 19, 2021). Available at: https://www.dol.gov/sites/dolgov/files/EBSA/about-ebsa/our-activities/resource-center/faqs/aca-part-47.pdf

4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv (accessed continuously; 2024 update cited here)

5. Centers for Disease Control and Prevention / DHHS. US Public Health Service: Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2021 Update: A Clinical Practice Guideline. Available at: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf

6. Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021;385(7):595-608. doi:10.1056/NEJMoa2101016 (HPTN 083)

7. Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the Prevention of HIV-1 in Women: Results from HPTN 084, a Phase 3, Randomised Clinical Trial. N Engl J Med. 2021;385(7):623-632. doi:10.1056/NEJMoa2101016 (HPTN 084)

8. Mayer KH, Molina JM, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396(10246):239-254. doi:10.1016/S0140-6736(20)31065-5 (DISCOVER trial)

9. Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Virologic Suppression. N Engl J Med. 2020;382(12):1112-1123. doi:10.1056/NEJMoa1904398 (ATLAS)

10. Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2021;396(10267):1994-2005. doi:10.1016/S0140-6736(20)32666-0 (ATLAS-2M)

11. Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143-155. doi:10.1016/S0140-6736(18)32462-0 (GEMINI-1 and GEMINI-2)

12. Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet HIV. 2018;5(10):e533-e544. doi:10.1016/S2352-3018(18)30194-8 (Biktarvy registration trials)

13. Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at: https://clinicalinfo.hiv.gov/en/guidelines/perinatal (DHHS Perinatal Guidelines)

14. Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at: https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv (DHHS Pediatric Guidelines)